Showing results (361-370 of 484) with videos related to

Sort By:
Pageof 49
Brain Pathology (Zurich, Switzerland)|July 15, 2017
Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosisSam Loveless, James W Neal, Owain W Howell, et al.
American Journal of Physiology. Endocrinology and Metabolism|May 29, 2014
Hepatic glucose uptake and disposition during short-term high-fat vs. high-fructose feedingKatie C Coate, Guillaume Kraft, Mary Courtney Moore, et al.
Journal of Neuropathology and Experimental Neurology|November 7, 2006
Abeta species removal after abeta42 immunizationJames A R Nicoll, Edward Barton, Delphine Boche, et al.
JTO Clinical and Research Reports|September 2, 2025
Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of ResponseIris van 't Erve, Isabelle Blanchard, Judy Y Pagtama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2021
Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain MetastasisChloe C Su, Julie T Wu, Joel W Neal, et al.
Cancer Treatment and Research Communications|November 25, 2022
Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancerJacqueline V Aredo, Heather A Wakelee, Angela Bik-Yu Hui, et al.
The American Journal of Physiology|May 11, 1992
Role of hepatic nerves in response of liver to intraportal glucose delivery in dogsB Adkins-Marshall, M J Pagliassotti, J R Asher, et al.
Journal of Global Oncology|November 14, 2018
Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and VietnamKim-Son H Nguyen, Henning Stehr, Li Zhou, et al.
JTO Clinical and Research Reports|January 27, 2025
Afatinib and Necitumumab in <i>EGFR</i>-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase InhibitorsNathaniel J Myall, Jennifer G Whisenant, Joel W Neal, et al.
Pageof 49